3M molecule to be utilised in Spirig dermatology product

3M has licensed one of its immune response modifier (IRM) molecules to Spirig Pharma, a manufacturer of dermatological and dermocosmetic products and medical devices.

The molecule will be utilised by Spirig – which is known for its skin cancer protection device Daylong actinica – in the development of a new product designed to treat sun-damaged skin.

3M's drug delivery systems division develops a wide array of IRMs for a variety of uses, with products available in the fields of cancer, asthma and allergy treatment, as well as compounds for use as vaccine adjuvants.

It expects that the deal with Spirig, which has a number of EU-based subsidiary divisions in addition to its Swiss base, will expand the international reach of 3M products.

Dr Mark Tomai, vaccine business development director for 3M Drug Delivery Systems, said: "The molecule offers potential for treating patients that suffer from a variety of dermatologic conditions. 3M is very proud of the many IRMs we have been developing for a variety of uses."

Last month, 3M launched new software for its Littmann Electronic Stethoscope Model 3200 in order to enable high-fidelity sound data transfers.